Purespring bags £80m to transform kidney disease treatment

Purespring’s innovation lies in targeting the podocyte, a critical cell involved in 60% of renal diseases, through the use of its adeno-associated viral (AAV) gene therapy platform. Their pipeline includes PS-002, targeting IgA Nephropathy and other complement-mediated kidney diseases, alongside programmes targeting nephrotic syndrome, among others.

This new funding will accelerate clinical progress, particularly the launch of a Phase I/II trial for IgAN—a chronic kidney disease with profound impact, leading to kidney failure and transplants for many within five years.

The financing follows critical scientific milestones for London-based Purespring. Earlier this year, the company presented preclinical data establishing the potential of AAV gene therapy to deliver transgenes to the podocyte to replace defective genes or to modulate protein production, underpinning the potential of AAV as an important novel modality to treat a broad range of kidney disease.

“Syncona founded Purespring with the vision of creating the world’s leading kidney gene therapy company,” commented Michael Kyriakides, Investment Partner at Syncona Investment Management and Board Director of Purespring Therapeutics. “Today’s financing and the strong syndicate of investors that the company has attracted broadens Purespring’s financial scale and clearly validates its technology, strategy and execution to date. We look forward to working alongside Purespring and its new syndicate as it prepares for its Phase I/II clinical trial.”